Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxone dose to block additional morphine effects in opioid-maintained patients
2007-001216-23Phase 4Completed
- Sponsor
- Phoenux
- Start
- Jun 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of naloxone in opioid use disorder (OUD) and heroin addiction, sponsored by Phoenux. Primary endpoint: Naloxone dose to block 200 mg morphine. Started Jun 2007; status: completed.
02
Drugs
naloxone
03
Conditions
opioid use disorder (OUD)heroin addiction
Beyond the preview
Go deeper on 2007-001216-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001216-23.